News | Heart Valve Technology | May 01, 2018

Edwards Granted CE Mark For First Transcatheter Tricuspid Therapy

Cardioband Tricuspid Valve Reconstruction System becomes first commercially available transcatheter therapy for treatment of tricuspid regurgitation

Edwards Granted CE Mark For First Transcatheter Tricuspid Therapy - Cardioband Tricuspid Valve Reconstruction System

May 1, 2018 — Edwards Lifesciences Corp.announced that it received CE Mark for the Edwards Cardioband Tricuspid Valve Reconstruction System for the treatment of tricuspid regurgitation. The Cardioband Tricuspid System is the first commercially available transcatheter therapy for the treatment of tricuspid heart valve disease.

"Although open-heart surgical valve repair is practiced today, it has not been performed frequently for those suffering from tricuspid regurgitation, despite evidence of increased mortality in these patients," said Prof. Georg Nickenig, chief, Department of Cardiology, University Hospital, Bonn, Germany. "Now with the European approval of the Cardioband Tricuspid System as the first transcatheter tricuspid therapy, patients can have access to a minimally invasive treatment designed to reduce tricuspid regurgitation and improve their symptoms and quality of life."

The Cardioband Tricuspid System is delivered via a transfemoral approach and is designed to reduce tricuspid regurgitation through annular reduction. It enables precise positioning to a patient's specific anatomy and real-time adjustment with simultaneous confirmation of results. It is the same design and implant technique as is used for the Cardioband Mitral System.

Read an article by Azeem Latib, M.D. on the early experience he had with the technology in "Transcatheter Annuloplasty For Repair Versus Replacement in Functional Mitral Regurgitation."

Watch the VIDEO "How to Implant the Transcatheter CardioBand Mitral Annuloplasty System."


Data on the Cardioband Tricuspid System will be presented at EuroPCR 2018, May 22-25 in Paris, france. The Cardioband System is not approved for commercial sale in the United States.

Edwards acquired the Cardioband System from Valtech Cardio in January 2017, and the receipt of the CE Mark is one of the pre-specified milestones that prompts a distribution of cash and stock totaling approximately $50 million to the former investors of Valtech Cardio.          

Prof. Nickenig has received compensation from Edwards for educational and training activities.

For more information:


Related Content

Boston Scientific Exercises Option to Acquire Millipede Inc.
News | Annuloplasty Rings | January 02, 2019
Boston Scientific Corp. exercised its option to acquire the remaining shares of Millipede Inc, a privately-held company...
LivaNova Receives FDA Clearance for Memo 4D Semi-Rigid Mitral Annuloplasty Ring
Technology | Annuloplasty Rings | June 15, 2018
LivaNova PLC announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Memo 4D semi-rigid...
Second Micro Interventional Devices Annuloplasty System Successfully Implanted
News | Annuloplasty Rings | October 30, 2017
Micro Interventional Devices Inc. (MID) recently announced the second successful implantation of its MIA (Minimally...
HAART 300 Aortic Annuloplasty Device Sees U.S. Pilot Launch, First Commercial Use
News | Annuloplasty Rings | July 05, 2017
July 5, 2017 — BioStable Science & Engineering Inc.
TITAN II Trial, Carillon Mitral Contour System, Cardiac Dimensions, Open Heart journal, functional mitral regurgitation, FMR
News | Annuloplasty Rings | July 20, 2016
New data from the TITAN II trial confirm the safety and efficacy of the Carillon Mitral Contour System in the treatment...
Mitralign Percutaneous Annuloplasty System, MPAS, CE Mark approval
News | Annuloplasty Rings | April 27, 2016
Mitralign Inc. announced its Mitralign Percutaneous Annuloplasty System (MPAS) has received CE mark approval from its...
Carillon mitral contour system, Cardiac Dimensions, functional mitral regurgitation, FMR, University Hospital Liepzig study
News | Annuloplasty Rings | February 24, 2016
A single-center study noted that treatment with Cardiac Dimensions’ Carillon Mitral Contour System resulted in...
Carillon mitral contour system, cost-effective, optimal medical treatment, OMT, TITAN, functional mitral regurgitation, FMR

Carillon mitral contour system image courtesy of Cardiac Dimensions Inc.

News | Annuloplasty Rings | September 10, 2015
The Carillon mitral contour system is projected to be a cost-effective treatment option when compared to a typical...